These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24049632)

  • 1. Sost, ECR5, Mef2C and van Buchem disease.
    Bonekey Rep; 2012; 1():204. PubMed ID: 24049632
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
    Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
    Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D
    St John HC; Hansen SJ; Pike JW
    J Steroid Biochem Mol Biol; 2016 Nov; 164():277-280. PubMed ID: 26361013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sost, independent of the non-coding enhancer ECR5, is required for bone mechanoadaptation.
    Robling AG; Kang KS; Bullock WA; Foster WH; Murugesh D; Loots GG; Genetos DC
    Bone; 2016 Nov; 92():180-188. PubMed ID: 27601226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.
    Balemans W; Patel N; Ebeling M; Van Hul E; Wuyts W; Lacza C; Dioszegi M; Dikkers FG; Hildering P; Willems PJ; Verheij JB; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
    J Med Genet; 2002 Feb; 39(2):91-7. PubMed ID: 11836356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and regulation of the SOST gene].
    Qin LJ; Ding DX; Cui LL; Huang QY
    Yi Chuan; 2013 Aug; 35(8):939-47. PubMed ID: 23956082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
    Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
    J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.
    Wergedal JE; Veskovic K; Hellan M; Nyght C; Balemans W; Libanati C; Vanhoenacker FM; Tan J; Baylink DJ; Van Hul W
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5778-83. PubMed ID: 14671168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
    Loots GG; Kneissel M; Keller H; Baptist M; Chang J; Collette NM; Ovcharenko D; Plajzer-Frick I; Rubin EM
    Genome Res; 2005 Jul; 15(7):928-35. PubMed ID: 15965026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
    Staehling-Hampton K; Proll S; Paeper BW; Zhao L; Charmley P; Brown A; Gardner JC; Galas D; Schatzman RC; Beighton P; Papapoulos S; Hamersma H; Brunkow ME
    Am J Med Genet; 2002 Jun; 110(2):144-52. PubMed ID: 12116252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.
    Balemans W; Cleiren E; Siebers U; Horst J; Van Hul W
    Bone; 2005 Jun; 36(6):943-7. PubMed ID: 15869924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mef2c deletion in osteocytes results in increased bone mass.
    Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
    J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
    van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
    Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.
    Kim SJ; Bieganski T; Sohn YB; Kozlowski K; Semënov M; Okamoto N; Kim CH; Ko AR; Ahn GH; Choi YL; Park SW; Ki CS; Kim OH; Nishimura G; Unger S; Superti-Furga A; Jin DK
    Hum Genet; 2011 May; 129(5):497-502. PubMed ID: 21221996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β regulates sclerostin expression via the ECR5 enhancer.
    Loots GG; Keller H; Leupin O; Murugesh D; Collette NM; Genetos DC
    Bone; 2012 Mar; 50(3):663-9. PubMed ID: 22155511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
    Balemans W; Ebeling M; Patel N; Van Hul E; Olson P; Dioszegi M; Lacza C; Wuyts W; Van Den Ende J; Willems P; Paes-Alves AF; Hill S; Bueno M; Ramos FJ; Tacconi P; Dikkers FG; Stratakis C; Lindpaintner K; Vickery B; Foernzler D; Van Hul W
    Hum Mol Genet; 2001 Mar; 10(5):537-43. PubMed ID: 11181578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
    van Bezooijen RL; Papapoulos SE; Löwik CW
    J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review.
    van Egmond ME; Dikkers FG; Boot AM; van Lierop AH; Papapoulos SE; Brouwer OF
    Eur J Paediatr Neurol; 2012 Nov; 16(6):740-3. PubMed ID: 22445802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Van Buchem disease: lifetime evolution of radioclinical features.
    Vanhoenacker FM; Balemans W; Tan GJ; Dikkers FG; De Schepper AM; Mathysen DG; Bernaerts A; Hul WV
    Skeletal Radiol; 2003 Dec; 32(12):708-18. PubMed ID: 14520501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.